OnKure Therapeutics will present preliminary data from the OKI-219 trial at SABCS on December 12, 2024.
Quiver AI Summary
OnKure Therapeutics, Inc. has announced that selected posters, including preliminary data from their PIKture-01 trial of OKI-219, will be presented at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS). Key details of the trial, which focuses on a mutant-selective inhibitor for advanced solid tumors, will be discussed in an investor call scheduled for December 10, 2024, at 7:00 a.m. CT, moving from the previously planned date of December 13. The posters will showcase findings related to OKI-219's effectiveness, with presentations on December 12. OnKure's ongoing research aims to develop targeted therapies for cancer, with OKI-219 as a lead candidate, highlighting their commitment to addressing underserved cancer types. Further details and updates will be made available on their website following the symposium.
Potential Positives
- OnKure Therapeutics is presenting preliminary data from its first-in-human PIKture-01 trial of OKI-219 at the prestigious San Antonio Breast Cancer Symposium, highlighting its innovative approach in oncology.
- The company is holding an investor call to review this new data, indicating its commitment to transparency and investor engagement.
- OKI-219 is positioned as a potentially significant treatment option for advanced solid tumors, which could enhance OnKure's profile in the biopharmaceutical industry.
- The poster presentations will include additional data on the efficacy of OKI-219 with standard of care therapies in mutant breast cancer models, suggesting promising research outcomes.
Potential Negatives
- Changing the date of the investor call from December 13 to December 10 may indicate urgency or concern regarding the preliminary data, which could raise questions about the robustness of the findings.
- The need to publish preliminary data from the clinical trial could suggest that definitive results have not yet been achieved, potentially undermining investor confidence.
- Investors may view the reliance on forward-looking statements as a sign of risk and uncertainty regarding the company's future prospects and the development of their product candidates.
FAQ
What is OnKure Therapeutics announcing?
OnKure is announcing poster presentations and an investor call regarding the preliminary data from the PIKture-01 trial of OKI-219.
When will the investor call take place?
The investor call will be held on Tuesday, December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET).
How can I access the presentation of the PIKture-01 trial?
The presentation can be accessed through a conference call or webcast available on OnKure's website.
What is the focus of the PIKture-01 clinical trial?
The PIKture-01 trial focuses on OKI-219 as a treatment for advanced solid tumors and advanced breast cancer.
Where can I find more information about OnKure and its projects?
More information about OnKure and its ongoing projects can be found on their official website at .
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10
th
.
OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. ET). The Company had previously announced the investor call would be held on Friday, December 13, 2024. To join the call, please dial 877-407-0789 (domestic), 201-689-8562 (international) and refer to conference ID 13750009. The call may also be accessed via webcast (
click here
) or from the Events page of the Investors section of the Company's website at
. A replay of the webcast will be available on OnKure's website for at least 30 days following the call.
In addition, today, SABCS published the full text from all regular abstracts on its website (
click here
). OnKure plans to include additional data in the posters being presented at SABCS, which will be made available on the Company's website after the poster is presented.
There are no changes to the planned in-person poster presentations at SABCS, which is taking place in San Antonio, Texas.
Poster presentation details:
Poster Title:
Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant
selective inhibitor of PI3Kα
H1047R
, in mutant selected solid tumors including breast cancer
Author:
Alexander Spira, MD, PhD, et al.
Presentation ID:
P3-08-19
Poster Session:
Poster Session 3
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 12:30 PM to 2:00 PM CST
Abstract Number:
SESS-3634
Poster Title:
OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3Kα
H1047R
mutant breast cancer models
Author:
Molly Taylor, PhD, et al.
Presentation ID:
P4-12-20
Poster Session:
Poster Session 4
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 05:30 PM to 7:00 PM CST
Abstract Number:
SESS-2240
For more details about SABCS please visit:
.
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a first-in-human study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as monotherapy in participants with advanced solid tumors and in combination with endocrine therapy or HER2-Targeted Therapy in participants with advanced breast cancer. Additional information about PIKture-01 may be found at
, using Identifier: NCT06239467.
About OnKure
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα
H1047R
inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
For more information about OnKure, visit us at
and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, OnKure's product candidates and programs, including OKI-219; OnKure's ability to advance additional programs; the expected milestones and timing of such milestones, including for OKI-219 and its discovery programs; and statements regarding OnKure's financial position, including its liquidity, cash runway and the sufficiency of its cash resources. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially" "will" or the negative of these terms or other similar expressions.
The company based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, those risks described in the section entitled "Risk Factors" in documents that OnKure files from time to time with the Securities and Exchange Commission ("SEC"), including the final 424B3 proxy statement/prospectus filed with the SEC on August 26, 2024. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.
Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
